Abstract 3620
Background
BAY 1436032 (BAY) inhibits R132X-mIDH1, which aberrantly generates oncometabolite 2-hydroxyglutarate (2-HG). In animal studies, BAY decreased 2-HG levels in mIDH1 tumours and showed brain penetration (brain/plasma ratio ∼0.2). Plasma 2-HG levels are increased in pts with mIDH1 tumours like intrahepatic cholangiocarcinoma (IHCC), but not in mIDH1 gliomas.
Methods
In this ongoing phase I dose-escalation and expansion study, BAY was administered orally (150-1500 mg BID) to pts with advanced mIDH1-R132X solid tumours. 4 expansion cohorts (1500 mg BID) enrolled pts with anaplastic and advanced grade 2 gliomas, glioblastoma (GBM), IHCC and other tumours. Response was assessed by RECIST (solid tumours) and RANO criteria (gliomas). Plasma BAY and 2-HG levels were measured.
Results
29 pts were treated in the escalation part in 5 dose-escalation cohorts and 52 in the expansion part. Pts had glioma (n = 55), IHCC (n = 16), chondrosarcoma (n = 7) and other tumours (n = 3). As of the 8 Nov 2018 preliminary cut-off, the most common all-cause treatment-emergent AEs reported in ≥ 10% of pts were: headache (20%), vomiting, diarrhoea and fatigue (19% each), nausea (16%), ALT increased (12%) and blood bilirubin increased (11%). There was 1 DLT (grade 3 rash maculopapular, 1500 mg BID). MTD was not reached; RP2D was 1500 mg BID. BAY exposure increased broadly dose proportionally from 150-1200 mg, with high variability. Consistent with short half-life, no accumulation was observed. Plasma 2-HG reduction occurred in nearly all non-glioma pts, with up to 98% inhibition. A pt with anaplastic astrocytoma (AA) (1200 mg BID) achieved complete response and is still on treatment (>23 months at cut-off); 2 glioma pts (AA and oligodendroglioma, both 1500 mg BID) had a partial response. 6 additional pts remained on treatment with stable disease at cut-off (3 gliomas, 2 GBM, 1 IHCC; treatment duration 4-11 months). Updated safety, efficacy and PK/PD analyses will be presented.
Conclusions
BAY is well tolerated as anticipated due to specificity for mIDH1. BAY inhibited mIDH1-R132X activity as evidenced by a PD effect in pts with measurable 2-HG, with objective response in 3 pts (all gliomas).
Clinical trial identification
NCT02746081.
Editorial acknowledgement
Medical writing assistance was provided by Laura Valenzo, PhD, of Complete Health Vizion and funded by Bayer AG.
Legal entity responsible for the study
Bayer AG.
Funding
Bayer AG.
Disclosure
W. Wick: Non-remunerated activity/ies, patent: IDH vaccine; Non-remunerated activity/ies, patent: IDH diagnostic; Non-remunerated activity/ies, patent: APG diagnostic. G. Tabatabai: Research grant / Funding (self): Roche Diagnostics; Research grant / Funding (self): Medac; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Novocure; Travel / Accommodation / Expenses: Medac; Speaker Bureau / Expert testimony: Medac; Speaker Bureau / Expert testimony: Novocure; Advisory / Consultancy: AbbVie; Advisory / Consultancy: BMS; Advisory / Consultancy: TIGER NIS (Novocure); Advisory / Consultancy: ON-TRK NIS (Bayer). M. Schuler: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Honoraria (self): Abbvie; Honoraria (self): Alexion; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Celgene; Honoraria (self): Lilly; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): Pierre Fabre; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Bristol Myers-Squibb; Research grant / Funding (institution): Novartis. K. Rorhberg: Research grant / Funding (self), Non-remunerated activity/ies: Bayer; Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Roche; Research grant / Funding (self), Non-remunerated activity/ies: Loxo Oncology; Research grant / Funding (self), Non-remunerated activity/ies: Orion Pharma; Research grant / Funding (self), Non-remunerated activity/ies: Pfizer; Research grant / Funding (self), Non-remunerated activity/ies: PUMA; Research grant / Funding (self), Non-remunerated activity/ies: Cantargia; Research grant / Funding (self), Non-remunerated activity/ies: Genmab; Research grant / Funding (self), Non-remunerated activity/ies: Novartis; Research grant / Funding (self), Non-remunerated activity/ies: Incyte; Research grant / Funding (self), Non-remunerated activity/ies: Symphogen; Research grant / Funding (self), Non-remunerated activity/ies: AstraZeneca; Research grant / Funding (self), Non-remunerated activity/ies: Alligator; Research grant / Funding (self), Non-remunerated activity/ies: Merck; Travel / Accommodation / Expenses: Sanofi; Research grant / Funding (self), Non-remunerated activity/ies: BMS. S.P. Chawla: Research grant / Funding (self): Amgen; Research grant / Funding (self): Roche; Research grant / Funding (self): Threshold Pharmaceuticals; Research grant / Funding (self): GlaxoSmithKline; Research grant / Funding (self): Immune Design; Research grant / Funding (self): TRACON Pharma; Research grant / Funding (self): SARC; Research grant / Funding (self): Karyopharma Therapeutics; Research grant / Funding (self): Jansen. F. Janku: Research grant / Funding (self): Novartis; Research grant / Funding (self): Genentech; Research grant / Funding (self): Bayer; Research grant / Funding (self): BioMed Valley Discoveries; Research grant / Funding (self): Astellas; Research grant / Funding (self): Agios; Research grant / Funding (self): Plexxikon; Research grant / Funding (self): Deciphera; Research grant / Funding (self): Piqur; Research grant / Funding (self): Symphogen; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): Asana; Research grant / Funding (self): Upsher-Smith Laboratories; Advisory / Consultancy: Guardant Health; Advisory / Consultancy: IFM Therapeutics; Advisory / Consultancy: Synlogic; Advisory / Consultancy: Deciphera; Advisory / Consultancy: Trovagene; Advisory / Consultancy: Immunomet; Shareholder / Stockholder / Stock options: Trovagene. Y. Narita: Speaker Bureau / Expert testimony, Research grant / Funding (self): Chugai Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (self): Ono Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (self): Abbvie; Speaker Bureau / Expert testimony, Research grant / Funding (self): Dainippon-Sumitomo; Speaker Bureau / Expert testimony, Research grant / Funding (self): Daiichi-Sankyo; Speaker Bureau / Expert testimony, Research grant / Funding (self): Eisai; Speaker Bureau / Expert testimony, Research grant / Funding (self): Stella-pharma; Speaker Bureau / Expert testimony, Research grant / Funding (self): Ohtuka; Speaker Bureau / Expert testimony, Research grant / Funding (self): Meiji-seika; Speaker Bureau / Expert testimony, Research grant / Funding (self): SBI pharma. Y. Ando: Honoraria (self), Research grant / Funding (self): Chugai Pharmaceutical Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Kyowa Hakko Kirin Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Nippon Kayaku Co., Ltd.; Honoraria (self), Research grant / Funding (self): Yakult Honsha Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Eli Lilly Japan K.K.; Honoraria (self), Research grant / Funding (self): Mochida Pharmaceutical Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Ono Pharmaceutical Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Taiho Pharmaceutical Co.,Ltd.; Honoraria (self): Novartis Pharma K.K.; Honoraria (self): Merck Serono Co.,Ltd.; Honoraria (self): Bayer Holding Ltd.; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Otsuka Holdings Co.,Ltd.; Honoraria (self): Sawai Pharmaceutical Co., Ltd; Honoraria (self), Research grant / Funding (self): Daiichi Sankyo Company, Ltd.; Research grant / Funding (self): Eisai Co.,Ltd.; Research grant / Funding (self): Hisamitsu Pharmaceutical Co., Inc.; Research grant / Funding (self): Takeda Pharmaceutical Co.,Ltd.; Honoraria (self): Tsumura & Co.; Honoraria (self): Shionogi & Co.,Ltd; Honoraria (self): Janssen Pharmaceutical K.K.; Honoraria (self): Pharma International Inc. H.J. Lenz: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck KG. M. Ikeda: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eisai; Honoraria (self), Advisory / Consultancy: MSD; Research grant / Funding (self): Ono; Advisory / Consultancy, Research grant / Funding (self): ASLAN; Honoraria (self), Research grant / Funding (self): Yakult; Research grant / Funding (self): J-Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eli Lilly; Honoraria (self), Research grant / Funding (self): Sumitomo Dainippon; Research grant / Funding (self): Kowa; Honoraria (self): Abbott; Honoraria (self): EA Pharma; Advisory / Consultancy, Research grant / Funding (self): Chugai; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy: Teijin Pharma; Advisory / Consultancy, Research grant / Funding (self): Kyowa Hakko Kirin; Advisory / Consultancy, Research grant / Funding (self): NanoCarrier; Advisory / Consultancy: Shire; Honoraria (self), Research grant / Funding (self): Taiho; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Baxalta; Research grant / Funding (self): Merck Serono; Advisory / Consultancy, Research grant / Funding (self): Takara Bio; Research grant / Funding (self): Zeria; Honoraria (self): Nobelpharma; Honoraria (self), Advisory / Consultancy: Otsuka; Honoraria (self): Kaken Pharmaceutical; Honoraria (self): Gilead; Advisory / Consultancy: Astellas Pharma; Research grant / Funding (self): Takeda Pharmaceutical; Advisory / Consultancy: Micron. I. Genvresse: Full / Part-time employment: Bayer AG. C. Rentzsch: Full / Part-time employment: Bayer AG. S. Reschke: Full / Part-time employment: Bayer AG. C. Cyris: Full / Part-time employment: CHRESTOS Concept GmbH & Co. KG. C. Cai: Full / Part-time employment: Bayer HealthCare Pharmaceuticals, Inc. M. Jeffers: Full / Part-time employment: Bayer HealthCare Pharmaceuticals, Inc. C. Peña: Full / Part-time employment: Bayer HealthCare Pharmaceuticals, Inc. O. Bähr: Honoraria (self): Novocure; Honoraria (self): Medac Pharma; Honoraria (self): BMS. All other authors have declared no conflicts of interest.
Resources from the same session
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract
4369 - Biomarker testing of lung cancer in Spain
Presenter: Delvys Rodriguez Abreu
Session: Poster Display session 1
Resources:
Abstract